@article{Sofronievska-Glavinov_Jovevska_Kocubovski_2019, title={Quality of life assessment in patients treated with medicaments for benign prostatic hyperplasia}, volume={11}, url={https://www.id-press.eu/aph/article/view/2860}, DOI={10.3889/aph.2019.2860}, abstractNote={<p>The purpose of this study was to determine the impact of symptoms and the effects of drug treatment on the quality of life in patients with benign prostatic hyperplasia. We evaluated two groups of patients with the International Prostate Scoring System questionnaire, the Beck depression inventory and an issue/question on quality of life. The first (control) group consisted of patients with benign prostatic hyperplasia who were on alpha-blocker therapy, while the second group of patients (examined) were on combination therapy with alpha blocker and 5-alpha reductase inhibitor. In analyzing the results, we came to the conclusion that patients in the control group had a better quality of life and psychosocial status due to the weaker symptoms of the disease. Patients in the second group had a poorer quality of life due to development of side effects of 5-alpha reductase inhibitors therapy: erectile dysfunction and depression. Modalities in the therapeutic approach enable improvement of the symptoms in the second group and improvement of the quality of life in patients with dual therapy for BPH.</p>}, number={1}, journal={Archives of Public Health}, author={Sofronievska-Glavinov, Maja and Jovevska, Svetlana and Kocubovski, Mihail}, year={2019}, month={Apr.}, pages={89–94} }